chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Dizziness, Dysgeusia, Feeling hot, Flushing, Presyncope
Clinical narrative: Immediate metallic taste, lightheadedness, warm sensation head to toe, almost passing out (did not pass out, was always conscious ), tachycardia, flushed skin, this lasted 5 minutes.  It did subside.; Immediate metallic taste, lightheadedness, warm sensation head to toe, almost passing out (did not pass out, was always conscious ), tachycardia, flushed skin, this lasted 5 minutes.  It did subside.; Immediate metallic taste, lightheadedness, warm sensation head to toe, almost passing out (did not pass out, was always conscious ), tachycardia, flushed skin, this lasted 5 minutes.  It did subside.; almost passing out (did not pass out, was always conscious); tachycardia, flushed skin this lasted 5 minutes. It did subside. Later that  day had localized hives that went away; tachycardia, flushed skin this lasted 5 minutes. It did subside. Later that  day had localized hives that went away; localized hives that went away; This is a spontaneous report from a contactable consumer. A 32-year-old non-pregnant female patient (not pregnant at the time of vaccination) received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; formulation: Solution for injection, Lot Number: EW0153) via an unspecified route of administration administered in left arm on 06Apr2021 12:00 Pm (at the age of 32-years-old) as a single dose for covid-19 immunisation. Medical history included autoimmune disorder. Concomitant medication(s) included mycophenolate mofetil (CELLCEPT [MYCOPHENOLATE MOFETIL]) taken for an unspecified indication, start and stop date were not reported. patient had known allergies Penicillin, shellfish, contrast dye. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 12:00 Pm, the patient experienced Immediate metallic taste, light-headedness, warm sensation head to toe, almost passing out (did not pass out, was always conscious), tachycardia, flushed skin, this lasted 5 minutes. It did subside. Later that day had localized hives that went away. No treatment received for adverse events. The outcome of the event flushed skin was recovered on 06Apr2021 12:05 and other events were recovered on unspecified date on 2021.  No follow up attempts are possible. Information about lot/batch number cannot be requested.
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Tachycardia, Urticaria
Clinical narrative: Immediate metallic taste, lightheadedness, warm sensation head to toe, almost passing out (did not pass out, was always conscious ), tachycardia, flushed skin, this lasted 5 minutes.  It did subside.; Immediate metallic taste, lightheadedness, warm sensation head to toe, almost passing out (did not pass out, was always conscious ), tachycardia, flushed skin, this lasted 5 minutes.  It did subside.; Immediate metallic taste, lightheadedness, warm sensation head to toe, almost passing out (did not pass out, was always conscious ), tachycardia, flushed skin, this lasted 5 minutes.  It did subside.; almost passing out (did not pass out, was always conscious); tachycardia, flushed skin this lasted 5 minutes. It did subside. Later that  day had localized hives that went away; tachycardia, flushed skin this lasted 5 minutes. It did subside. Later that  day had localized hives that went away; localized hives that went away; This is a spontaneous report from a contactable consumer. A 32-year-old non-pregnant female patient (not pregnant at the time of vaccination) received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; formulation: Solution for injection, Lot Number: EW0153) via an unspecified route of administration administered in left arm on 06Apr2021 12:00 Pm (at the age of 32-years-old) as a single dose for covid-19 immunisation. Medical history included autoimmune disorder. Concomitant medication(s) included mycophenolate mofetil (CELLCEPT [MYCOPHENOLATE MOFETIL]) taken for an unspecified indication, start and stop date were not reported. patient had known allergies Penicillin, shellfish, contrast dye. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 12:00 Pm, the patient experienced Immediate metallic taste, light-headedness, warm sensation head to toe, almost passing out (did not pass out, was always conscious), tachycardia, flushed skin, this lasted 5 minutes. It did subside. Later that day had localized hives that went away. No treatment received for adverse events. The outcome of the event flushed skin was recovered on 06Apr2021 12:05 and other events were recovered on unspecified date on 2021.  No follow up attempts are possible. Information about lot/batch number cannot be requested.
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Dizziness, Dysgeusia, Feeling hot, Flushing, Heart rate
Clinical narrative: Immediate metallic taste, lightheadedness, warm sensation head to toe, almost passing out (did not pass out, was always conscious ), tachycardia, flushed skin, this lasted 5 minutes.  It did subside.; Immediate metallic taste, lightheadedness, warm sensation head to toe, almost passing out (did not pass out, was always conscious ), tachycardia, flushed skin, this lasted 5 minutes.  It did subside.; Immediate metallic taste, lightheadedness, warm sensation head to toe, almost passing out (did not pass out, was always conscious ), tachycardia, flushed skin, this lasted 5 minutes.  It did subside.; almost passing out (did not pass out, was always conscious); tachycardia, flushed skin this lasted 5 minutes. It did subside. Later that  day had localized hives that went away; tachycardia, flushed skin this lasted 5 minutes. It did subside. Later that  day had localized hives that went away; localized hives that went away; This is a spontaneous report from a contactable consumer. A 32-year-old non-pregnant female patient (not pregnant at the time of vaccination) received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; formulation: Solution for injection, Lot Number: EW0153) via an unspecified route of administration administered in left arm on 06Apr2021 12:00 Pm (at the age of 32-years-old) as a single dose for covid-19 immunisation. Medical history included autoimmune disorder. Concomitant medication(s) included mycophenolate mofetil (CELLCEPT [MYCOPHENOLATE MOFETIL]) taken for an unspecified indication, start and stop date were not reported. patient had known allergies Penicillin, shellfish, contrast dye. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 12:00 Pm, the patient experienced Immediate metallic taste, light-headedness, warm sensation head to toe, almost passing out (did not pass out, was always conscious), tachycardia, flushed skin, this lasted 5 minutes. It did subside. Later that day had localized hives that went away. No treatment received for adverse events. The outcome of the event flushed skin was recovered on 06Apr2021 12:05 and other events were recovered on unspecified date on 2021.  No follow up attempts are possible. Information about lot/batch number cannot be requested.
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Heart rate increased, Urticaria
Clinical narrative: Immediate metallic taste, lightheadedness, warm sensation head to toe, almost passing out (did not pass out, was always conscious ), tachycardia, flushed skin, this lasted 5 minutes.  It did subside.; Immediate metallic taste, lightheadedness, warm sensation head to toe, almost passing out (did not pass out, was always conscious ), tachycardia, flushed skin, this lasted 5 minutes.  It did subside.; Immediate metallic taste, lightheadedness, warm sensation head to toe, almost passing out (did not pass out, was always conscious ), tachycardia, flushed skin, this lasted 5 minutes.  It did subside.; almost passing out (did not pass out, was always conscious); tachycardia, flushed skin this lasted 5 minutes. It did subside. Later that  day had localized hives that went away; tachycardia, flushed skin this lasted 5 minutes. It did subside. Later that  day had localized hives that went away; localized hives that went away; This is a spontaneous report from a contactable consumer. A 32-year-old non-pregnant female patient (not pregnant at the time of vaccination) received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; formulation: Solution for injection, Lot Number: EW0153) via an unspecified route of administration administered in left arm on 06Apr2021 12:00 Pm (at the age of 32-years-old) as a single dose for covid-19 immunisation. Medical history included autoimmune disorder. Concomitant medication(s) included mycophenolate mofetil (CELLCEPT [MYCOPHENOLATE MOFETIL]) taken for an unspecified indication, start and stop date were not reported. patient had known allergies Penicillin, shellfish, contrast dye. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 12:00 Pm, the patient experienced Immediate metallic taste, light-headedness, warm sensation head to toe, almost passing out (did not pass out, was always conscious), tachycardia, flushed skin, this lasted 5 minutes. It did subside. Later that day had localized hives that went away. No treatment received for adverse events. The outcome of the event flushed skin was recovered on 06Apr2021 12:05 and other events were recovered on unspecified date on 2021.  No follow up attempts are possible. Information about lot/batch number cannot be requested.
Age: 68.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Headache, Herpes zoster
Clinical narrative: Sharp stabbing Headaches began 4 th day following second Pfizer shot; Shingles on left head and face/ eye; Shingles on left head and face/ eye/ Shingles Rash exhibited 6 days after that; This is a spontaneous report from a contactable consumer (patient). This 68-year-old-male patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; lot number EN6208) via an unspecified route of administration in the left arm on 18Mar2021 at 17:00 (at 68-years-old) as a single dose for COVID-19 immunisation. Medical history included high cholesterol controlled by medication from an unknown date. The patient had no allergies to medications, food or other products. Concomitant medications included ascorbic acid (vitamin C), simvastatin, and acetylsalicylic acid (ASPIRIN) 81 mg, all from unknown dates for unknown indications. The patient previously received the first dose of BNT162B2 (lot number EV6203) in the left arm on 25Feb2021 at 17:00 (at 68-years-old) for COVID-19 immunisation. Prior to vaccination the patient was not diagnosed with COVID-19 and had not received any other vaccines in the four weeks prior to the COVID vaccine. On 22Mar2021 the patient experienced sharp stabbing headaches that began the fourth day following second Pfizer shot; and on an unspecified date in Mar2021 the patient experienced shingles on left head and face/eye and shingles rash exhibited 6 days after "that." The events required an emergency department visit and physician office visit; it was unknown if treatment was received for the events. The clinical outcomes of the events were recovering. Since vaccination the patient had not been tested for COVID-19.
Age: 68.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Headache, Herpes zoster, Ophthalmic herpes zoster
Clinical narrative: Sharp stabbing Headaches began 4 th day following second Pfizer shot; Shingles on left head and face/ eye; Shingles on left head and face/ eye/ Shingles Rash exhibited 6 days after that; This is a spontaneous report from a contactable consumer (patient). This 68-year-old-male patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; lot number EN6208) via an unspecified route of administration in the left arm on 18Mar2021 at 17:00 (at 68-years-old) as a single dose for COVID-19 immunisation. Medical history included high cholesterol controlled by medication from an unknown date. The patient had no allergies to medications, food or other products. Concomitant medications included ascorbic acid (vitamin C), simvastatin, and acetylsalicylic acid (ASPIRIN) 81 mg, all from unknown dates for unknown indications. The patient previously received the first dose of BNT162B2 (lot number EV6203) in the left arm on 25Feb2021 at 17:00 (at 68-years-old) for COVID-19 immunisation. Prior to vaccination the patient was not diagnosed with COVID-19 and had not received any other vaccines in the four weeks prior to the COVID vaccine. On 22Mar2021 the patient experienced sharp stabbing headaches that began the fourth day following second Pfizer shot; and on an unspecified date in Mar2021 the patient experienced shingles on left head and face/eye and shingles rash exhibited 6 days after "that." The events required an emergency department visit and physician office visit; it was unknown if treatment was received for the events. The clinical outcomes of the events were recovering. Since vaccination the patient had not been tested for COVID-19.
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Body temperature increased, Diarrhoea, Pain, SARS-CoV-2 test negative
Clinical narrative: Diarrhea for several days; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 73121) via an unspecified route of administration on 29Mar2021 (at the age of 45-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On an unknown date in 2021, the patient experienced diarrhea for several days. The patient underwent lab tests and procedures which included COVID-19 virus test on an unknown date in 2021 (post vaccination) and tested negative. The clinical outcome of the event diarrhea was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Diarrhoea, SARS-CoV-2 test
Clinical narrative: Diarrhea for several days; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 73121) via an unspecified route of administration on 29Mar2021 (at the age of 45-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On an unknown date in 2021, the patient experienced diarrhea for several days. The patient underwent lab tests and procedures which included COVID-19 virus test on an unknown date in 2021 (post vaccination) and tested negative. The clinical outcome of the event diarrhea was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood pressure increased, Blood test, Dizziness, Fatigue, Heart rate increased
Clinical narrative: Fatigue; lightheaded; tiredness; blood pressure; Heart rate; This is a spontaneous report from a contactable other healthcare professional. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9261), via an unspecified route of administration in the left arm on 21Jan2021 at 15:45 (at the age of 41-year-old) and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200), via an unspecified route of administration in the right arm on 19Feb2021(at the age of 41-year-old), as a single dose for COVID-19 immunisation. Medical history included maintained blood pressure and the patient had a history of allergies to cherries, plums, nectarine. Concomitant medications included hydrochlorothiazide (MANUFACTURER UNKNOWN) of dose 25 milligram for an unknown indication. The patient did not receive the other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 18Feb2021 at 10:00, the patient experienced fatigue, lightheaded, tiredness, blood pressure and heart rate was at 114 at rest and at the time of this report it was consistently at 90bpm(beats per minute) at rest. On an unknown date, the patient underwent lab tests and procedures which included heart rate test and the result was 114 at rest and at the time of report it was 90 bpm at rest. On 02Jan2021, the patient underwent COVID-19 (nasal swab) test and the result was found to be negative. The events resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken for the events. The clinical outcome of the event  fatigue, lightheaded, tiredness, blood pressure and heart rate was not recovered at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Irritability, Magnetic resonance imaging abnormal, Migraine
Clinical narrative: Fatigue; lightheaded; tiredness; blood pressure; Heart rate; This is a spontaneous report from a contactable other healthcare professional. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9261), via an unspecified route of administration in the left arm on 21Jan2021 at 15:45 (at the age of 41-year-old) and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200), via an unspecified route of administration in the right arm on 19Feb2021(at the age of 41-year-old), as a single dose for COVID-19 immunisation. Medical history included maintained blood pressure and the patient had a history of allergies to cherries, plums, nectarine. Concomitant medications included hydrochlorothiazide (MANUFACTURER UNKNOWN) of dose 25 milligram for an unknown indication. The patient did not receive the other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 18Feb2021 at 10:00, the patient experienced fatigue, lightheaded, tiredness, blood pressure and heart rate was at 114 at rest and at the time of this report it was consistently at 90bpm(beats per minute) at rest. On an unknown date, the patient underwent lab tests and procedures which included heart rate test and the result was 114 at rest and at the time of report it was 90 bpm at rest. On 02Jan2021, the patient underwent COVID-19 (nasal swab) test and the result was found to be negative. The events resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken for the events. The clinical outcome of the event  fatigue, lightheaded, tiredness, blood pressure and heart rate was not recovered at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood pressure measurement, Dizziness, Fatigue, Heart rate, SARS-CoV-2 test
Clinical narrative: Fatigue; lightheaded; tiredness; blood pressure; Heart rate; This is a spontaneous report from a contactable other healthcare professional. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9261), via an unspecified route of administration in the left arm on 21Jan2021 at 15:45 (at the age of 41-year-old) and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200), via an unspecified route of administration in the right arm on 19Feb2021(at the age of 41-year-old), as a single dose for COVID-19 immunisation. Medical history included maintained blood pressure and the patient had a history of allergies to cherries, plums, nectarine. Concomitant medications included hydrochlorothiazide (MANUFACTURER UNKNOWN) of dose 25 milligram for an unknown indication. The patient did not receive the other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 18Feb2021 at 10:00, the patient experienced fatigue, lightheaded, tiredness, blood pressure and heart rate was at 114 at rest and at the time of this report it was consistently at 90bpm(beats per minute) at rest. On an unknown date, the patient underwent lab tests and procedures which included heart rate test and the result was 114 at rest and at the time of report it was 90 bpm at rest. On 02Jan2021, the patient underwent COVID-19 (nasal swab) test and the result was found to be negative. The events resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken for the events. The clinical outcome of the event  fatigue, lightheaded, tiredness, blood pressure and heart rate was not recovered at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Headache, Herpes zoster, Hypersensitivity, Nausea, Pain of skin
Clinical narrative: skin sensitivity with pain; skin sensitivity with pain; Pain and tenderness in scalp; Rash developed on neck and in scalp; After 2 Dr visits was diagnosed with Shingles.; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3302) via an unspecified route of administration on the right arm on 15Mar2021 at 12:00 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not receive any medication within two weeks of vaccination. The patient did not report any allergies to food, medications and other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Mar2021 at 12:00, the patient experienced skin sensitivity with pain, pain and tenderness in scalp, rash developed on the neck and in the scalp and shingles. The event resulted in doctor or other healthcare professional office/clinic visit and Emergency room/department or urgent care. Therapeutic measures were taken as a result of skin sensitivity with pain, pain and tenderness in scalp, rash developed on the neck and in the scalp and shingles included treatment with hydroxyzine, prednisone, valacyclovir & triamcinol.  The clinical outcome of the events skin sensitivity with pain, pain and tenderness in scalp, rash developed on the neck and in the scalp and shingles were not recovered at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Rash, Skin disorder, Swelling
Clinical narrative: skin sensitivity with pain; skin sensitivity with pain; Pain and tenderness in scalp; Rash developed on neck and in scalp; After 2 Dr visits was diagnosed with Shingles.; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3302) via an unspecified route of administration on the right arm on 15Mar2021 at 12:00 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not receive any medication within two weeks of vaccination. The patient did not report any allergies to food, medications and other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Mar2021 at 12:00, the patient experienced skin sensitivity with pain, pain and tenderness in scalp, rash developed on the neck and in the scalp and shingles. The event resulted in doctor or other healthcare professional office/clinic visit and Emergency room/department or urgent care. Therapeutic measures were taken as a result of skin sensitivity with pain, pain and tenderness in scalp, rash developed on the neck and in the scalp and shingles included treatment with hydroxyzine, prednisone, valacyclovir & triamcinol.  The clinical outcome of the events skin sensitivity with pain, pain and tenderness in scalp, rash developed on the neck and in the scalp and shingles were not recovered at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Herpes zoster, Lymphadenopathy, Pruritus, Rash
Clinical narrative: skin sensitivity with pain; skin sensitivity with pain; Pain and tenderness in scalp; Rash developed on neck and in scalp; After 2 Dr visits was diagnosed with Shingles.; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3302) via an unspecified route of administration on the right arm on 15Mar2021 at 12:00 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not receive any medication within two weeks of vaccination. The patient did not report any allergies to food, medications and other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Mar2021 at 12:00, the patient experienced skin sensitivity with pain, pain and tenderness in scalp, rash developed on the neck and in the scalp and shingles. The event resulted in doctor or other healthcare professional office/clinic visit and Emergency room/department or urgent care. Therapeutic measures were taken as a result of skin sensitivity with pain, pain and tenderness in scalp, rash developed on the neck and in the scalp and shingles included treatment with hydroxyzine, prednisone, valacyclovir & triamcinol.  The clinical outcome of the events skin sensitivity with pain, pain and tenderness in scalp, rash developed on the neck and in the scalp and shingles were not recovered at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Herpes zoster, Pain of skin, Rash, Sensitive skin
Clinical narrative: skin sensitivity with pain; skin sensitivity with pain; Pain and tenderness in scalp; Rash developed on neck and in scalp; After 2 Dr visits was diagnosed with Shingles.; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3302) via an unspecified route of administration on the right arm on 15Mar2021 at 12:00 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not receive any medication within two weeks of vaccination. The patient did not report any allergies to food, medications and other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Mar2021 at 12:00, the patient experienced skin sensitivity with pain, pain and tenderness in scalp, rash developed on the neck and in the scalp and shingles. The event resulted in doctor or other healthcare professional office/clinic visit and Emergency room/department or urgent care. Therapeutic measures were taken as a result of skin sensitivity with pain, pain and tenderness in scalp, rash developed on the neck and in the scalp and shingles included treatment with hydroxyzine, prednisone, valacyclovir & triamcinol.  The clinical outcome of the events skin sensitivity with pain, pain and tenderness in scalp, rash developed on the neck and in the scalp and shingles were not recovered at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 34.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Injection site pain, Pain
Clinical narrative: His arm ached within expectations after the injection; This is a spontaneous report from a contactable consumer. A 34-years-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration on 07Apr2021, (at the age of 34-years-old) as a single dose for COVID-19 immunisation. The relevant medical history and concomitant medications was not reported. It was unknown if the patient took any other vaccines in four weeks. Prior to the vaccination, the patient was not tested for COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 07Apr2021, the patient experienced arm ache within expectations after the injection and lessened by the next day. No therapeutic measures were taken as a result of the event. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event arm ache within expectations after the injection was recovering.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 34.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pain in extremity
Clinical narrative: His arm ached within expectations after the injection; This is a spontaneous report from a contactable consumer. A 34-years-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration on 07Apr2021, (at the age of 34-years-old) as a single dose for COVID-19 immunisation. The relevant medical history and concomitant medications was not reported. It was unknown if the patient took any other vaccines in four weeks. Prior to the vaccination, the patient was not tested for COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 07Apr2021, the patient experienced arm ache within expectations after the injection and lessened by the next day. No therapeutic measures were taken as a result of the event. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event arm ache within expectations after the injection was recovering.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 68.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Body temperature increased, Injection site erythema, Injection site pain, Injection site pruritus, Injection site rash
Clinical narrative: red splotches on right arm below site; burning; red bump/tiny white bumps left leg above knee, Left torso; temperature was 1-1.2 degrees above normal; 4x7 uniformly reddish area; itchiness on right arm below site; Itchiness on left side of torso; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733), via an unspecified route of administration in the right arm on 29Mar2021 at 10:00 (at the age of 68-year-old), as a single dose for COVID-19 immunisation. Medical history included low IgG, chronic lymphocytic leukemia (CLL) and the patient had a history of allergy to Neosporin slight, but bacitracin fine grass, cats and dust allergy. Concomitant medications included levetiracetam (KEPPRA) for an unknown indication from an unknown date. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202), via an unspecified route of administration in the right arm on 08Mar2021 at 10:00 (at the age of 68-year-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 02:00 morning after, temperature was 1-1.2 degrees above normal (by afternoon, back to normal), had 6 red splotches on right arm below site and red bumps on left leg above knee. Over next two days, spread into a 4" x 7" uniformly reddish area, some itchiness, some burning. The patient used warm compresses, switched to cool. By day 10, spread on arm halted. Itchiness elsewhere, left side of torso, small patch. Day 11, some fading, receding on arm. On day 12, better, but still pink and uncomfortable. Left torso still small itchy area, tiny white bumps. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken for the events itchiness on right arm below site and burning with warm and cold compressors. The clinical outcome of the event temperature was above normal was recovered on 03Apr2021 while the events red splotches, "4 x 7" uniformly reddish area, itchiness on right arm below site, burning, red bump/tiny white bumps and itchiness on left torso were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 68.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Rash, Rash pruritic
Clinical narrative: red splotches on right arm below site; burning; red bump/tiny white bumps left leg above knee, Left torso; temperature was 1-1.2 degrees above normal; 4x7 uniformly reddish area; itchiness on right arm below site; Itchiness on left side of torso; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733), via an unspecified route of administration in the right arm on 29Mar2021 at 10:00 (at the age of 68-year-old), as a single dose for COVID-19 immunisation. Medical history included low IgG, chronic lymphocytic leukemia (CLL) and the patient had a history of allergy to Neosporin slight, but bacitracin fine grass, cats and dust allergy. Concomitant medications included levetiracetam (KEPPRA) for an unknown indication from an unknown date. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202), via an unspecified route of administration in the right arm on 08Mar2021 at 10:00 (at the age of 68-year-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 02:00 morning after, temperature was 1-1.2 degrees above normal (by afternoon, back to normal), had 6 red splotches on right arm below site and red bumps on left leg above knee. Over next two days, spread into a 4" x 7" uniformly reddish area, some itchiness, some burning. The patient used warm compresses, switched to cool. By day 10, spread on arm halted. Itchiness elsewhere, left side of torso, small patch. Day 11, some fading, receding on arm. On day 12, better, but still pink and uncomfortable. Left torso still small itchy area, tiny white bumps. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken for the events itchiness on right arm below site and burning with warm and cold compressors. The clinical outcome of the event temperature was above normal was recovered on 03Apr2021 while the events red splotches, "4 x 7" uniformly reddish area, itchiness on right arm below site, burning, red bump/tiny white bumps and itchiness on left torso were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 68.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Body temperature increased, Erythema, Pruritus, Rash macular, Skin burning sensation
Clinical narrative: red splotches on right arm below site; burning; red bump/tiny white bumps left leg above knee, Left torso; temperature was 1-1.2 degrees above normal; 4x7 uniformly reddish area; itchiness on right arm below site; Itchiness on left side of torso; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733), via an unspecified route of administration in the right arm on 29Mar2021 at 10:00 (at the age of 68-year-old), as a single dose for COVID-19 immunisation. Medical history included low IgG, chronic lymphocytic leukemia (CLL) and the patient had a history of allergy to Neosporin slight, but bacitracin fine grass, cats and dust allergy. Concomitant medications included levetiracetam (KEPPRA) for an unknown indication from an unknown date. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202), via an unspecified route of administration in the right arm on 08Mar2021 at 10:00 (at the age of 68-year-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 02:00 morning after, temperature was 1-1.2 degrees above normal (by afternoon, back to normal), had 6 red splotches on right arm below site and red bumps on left leg above knee. Over next two days, spread into a 4" x 7" uniformly reddish area, some itchiness, some burning. The patient used warm compresses, switched to cool. By day 10, spread on arm halted. Itchiness elsewhere, left side of torso, small patch. Day 11, some fading, receding on arm. On day 12, better, but still pink and uncomfortable. Left torso still small itchy area, tiny white bumps. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken for the events itchiness on right arm below site and burning with warm and cold compressors. The clinical outcome of the event temperature was above normal was recovered on 03Apr2021 while the events red splotches, "4 x 7" uniformly reddish area, itchiness on right arm below site, burning, red bump/tiny white bumps and itchiness on left torso were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 68.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Skin disorder
Clinical narrative: red splotches on right arm below site; burning; red bump/tiny white bumps left leg above knee, Left torso; temperature was 1-1.2 degrees above normal; 4x7 uniformly reddish area; itchiness on right arm below site; Itchiness on left side of torso; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733), via an unspecified route of administration in the right arm on 29Mar2021 at 10:00 (at the age of 68-year-old), as a single dose for COVID-19 immunisation. Medical history included low IgG, chronic lymphocytic leukemia (CLL) and the patient had a history of allergy to Neosporin slight, but bacitracin fine grass, cats and dust allergy. Concomitant medications included levetiracetam (KEPPRA) for an unknown indication from an unknown date. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202), via an unspecified route of administration in the right arm on 08Mar2021 at 10:00 (at the age of 68-year-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 02:00 morning after, temperature was 1-1.2 degrees above normal (by afternoon, back to normal), had 6 red splotches on right arm below site and red bumps on left leg above knee. Over next two days, spread into a 4" x 7" uniformly reddish area, some itchiness, some burning. The patient used warm compresses, switched to cool. By day 10, spread on arm halted. Itchiness elsewhere, left side of torso, small patch. Day 11, some fading, receding on arm. On day 12, better, but still pink and uncomfortable. Left torso still small itchy area, tiny white bumps. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken for the events itchiness on right arm below site and burning with warm and cold compressors. The clinical outcome of the event temperature was above normal was recovered on 03Apr2021 while the events red splotches, "4 x 7" uniformly reddish area, itchiness on right arm below site, burning, red bump/tiny white bumps and itchiness on left torso were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Chills, Dehydration, Dyspnoea, Fatigue, Headache
Clinical narrative: Headache; Body aches; Difficulty taking full breaths; Insomnia; Chills; Sweating; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06Apr2021 at 12:00 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Concomitant medications included ashwagandha and multivitamins. The patient did not receive any other medications or vaccines within 4 weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 06Apr2021 at 07:00, the patient experienced headache, body aches, difficulty taking full breaths, insomnia, chills and sweating. On 06Apr2021, the patient underwent nasal swab test and the result was negative. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the events headache, body aches, difficulty taking full breaths, insomnia, chills and sweating were not resolved at the time of this report. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 27.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Hyperhidrosis, Injection site pain, Musculoskeletal stiffness, Nausea, Pain
Clinical narrative: Headache; Body aches; Difficulty taking full breaths; Insomnia; Chills; Sweating; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06Apr2021 at 12:00 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Concomitant medications included ashwagandha and multivitamins. The patient did not receive any other medications or vaccines within 4 weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 06Apr2021 at 07:00, the patient experienced headache, body aches, difficulty taking full breaths, insomnia, chills and sweating. On 06Apr2021, the patient underwent nasal swab test and the result was negative. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the events headache, body aches, difficulty taking full breaths, insomnia, chills and sweating were not resolved at the time of this report. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 27.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: SARS-CoV-2 test negative
Clinical narrative: Headache; Body aches; Difficulty taking full breaths; Insomnia; Chills; Sweating; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06Apr2021 at 12:00 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Concomitant medications included ashwagandha and multivitamins. The patient did not receive any other medications or vaccines within 4 weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 06Apr2021 at 07:00, the patient experienced headache, body aches, difficulty taking full breaths, insomnia, chills and sweating. On 06Apr2021, the patient underwent nasal swab test and the result was negative. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the events headache, body aches, difficulty taking full breaths, insomnia, chills and sweating were not resolved at the time of this report. No follow-up attempts are needed; information about lot/batch number cannot be obtained.